Latest From Medicure Inc.
Zydus says its Moraiya plant should be ready for re-inspection at the end of June 2020, following a recent FDA warning letter. Meanwhile, as returns from levorphanol fall on the back of increased competition, the firm has written down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
As returns from levorphanol fall on the back of increased competition, Zydus Cadila writes down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.
Zydus Cadila is teaming up with Canada’s Medicure Inc to launch cholesterol control medication Zypitamag, its first branded drug in the key US market, as the Indian firm drives ahead with a strategy of diversifying from low-priced generics.
- Therapeutic Areas
- Lariat Capital Inc.
- North America
- Parent & Subsidiaries
- Medicure Inc.
- Senior Management
Albert D Friesen, PhD, Chmn. & CEO
James Kinley, CFO
Neil Owens, PhD, Pres. & COO
- Contact Info
Phone: (204) 487-7412
2-1250 Waverly St.
Winnipeg, R3T 6C6
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.